| |
GeneSuites is the development manager for Catalyst BioCampus in North Carolina which is on track to support biomanufacturing by 2024. Learn more.
|
|
Today's Big NewsNov 29, 2022 |
| By Eric Sagonowsky While the pricing measures in Biden's Inflation Reduction Act slowly begin to come into effect starting next year, there are still major unknowns for pricing experts and industry watchers. |
|
|
|
By Andrea Park Canon is seeing stars (and stripes). The tech giant is making plans to open up its second medtech-focused subsidiary in the U.S., a move that it’s hoping will in turn bolster its position within the global medical device industry. |
By Nick Paul Taylor AstraZeneca is stepping up its pitch for a slice of the cell therapy space, paying $200 million upfront for a solid tumor player that recently hustled an autologous, fully individualized, multispecific prospect into the clinic. |
By Heather Landi Shares of online therapy company Talkspace jumped 40% Monday on news that telehealth provider Amwell is exploring a buyout. Reports of a possible deal come as Talkspace's shares have plummeted amid financial struggles and key executives leaving the company. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now.
|
|
By Fraiser Kansteiner AstraZeneca has locked in a sale of its site in West Chester, Ohio, to busy biomanufacturing newcomer National Resilience. In tandem with the sale, the drugmakers forged a “long-term” biomanufacturing accord under which Resilience will continue to crank out “select AstraZeneca medicines." |
By Nick Paul Taylor Bristol Myers Squibb is breaking off its collaboration and license agreement with uniQure, calling time on a pact that was intended to deliver gene therapies against multiple cardiovascular disease targets. |
By Conor Hale Boston Scientific has laid down a deal to acquire the gastrointestinal device company Apollo Endosurgery, with a cash offer totaling about $615 million. |
By Heather Landi The Direct Contracting Model saved Medicare $70 million in 2021 as the Biden administration plans a major overhaul to the value-based care program next year. |
By Kevin Dunleavy A week after GSK sidelined its multiple myeloma drug Blenrep, following a confirmatory trial failure, Roche has done the same for a key indication of its blockbuster cancer drug Tecentriq. Following consultation with the FDA, Roche has withdrawn Tecentriq's use as a first-line treatment for a form of advanced bladder cancer. The move is another in a growing list of accelerated approvals that have been overturned. |
By Gabrielle Masson While other biotechs are culling staff and programs to stay afloat, BigHat Biosciences has remained dry under its ever-expanding umbrella, this time inking a multiproject deal with Merck & Co. while growing its team 30% since the summer. |
By Andrea Park The latest version of Philips’ diagnostic imaging platform adds a handful of artificial-intelligence-powered programs that aim to hugely cut down on the time and effort it takes to turn a preliminary scan into a solid diagnosis. |
By Heather Landi Google Health struck a deal with medical technology company iCAD to integrate its artificial intelligence technology into the company's breast imaging solutions. |
By Fraiser Kansteiner After Amgen's recent advance in its patent feud with Regeneron and Sanofi, Bristol Myers Squibb is turning to the Supreme Court—yet again—in a bid to revive a blockbuster verdict. |
By Gabrielle Masson In efforts to dominate radiopharmaceutical R&D, Full-Life Technologies is set to acquire New Jersey biotech Focus-X Therapeutics for a price tag that could max out at $245 million. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss the challenges companies face in trying to provide healthcare coverage for their workers. We also talk about how to fix the broken healthcare system. |
|
|---|
|
|
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
